Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

Lenalidomide is a drug with clinical efficacy in multiple myeloma and other B cell neoplasms, but its mechanism of action is unknown. Using quantitative proteomics, we found that lenalidomide causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by t...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Krönke, Jan, Udeshi, Namrata D., Narla, Anupama, Grauman, Peter, Hurst, Slater N., McConkey, Marie, Svinkina, Tanya, Heckl, Dirk, Comer, Eamon, Li, Xiaoyu, Ciarlo, Christie, Hartman, Emily, Munshi, Nikhil, Schenone, Monica, Schreiber, Stuart L., Carr, Steven A., Ebert, Benjamin L.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2013
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4077049/
https://ncbi.nlm.nih.gov/pubmed/24292625
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/science.1244851
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak